Clinical Trial Update: A Trial of Anlotinib Combined With Docetaxel in EGFR Mutations Advanced Non Small Cell Lung Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating anlotinib plus docetaxel in EGFR-mutant advanced non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Shandong Cancer Hospital and Institute | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN